Get started
Author

Denise Shortino

Observed names: D Shortino, D. D. Shortino, Denise D. Shortino
OpenAlex ID: A5035835916
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
1996 · Robyn J. Barst, Lewis J. Rubin, et al. · New England Journal of Medicine · 2,698
PDF
Genetic variations in HLA-B region and hypersensitivity reactions to abacavir
2002 · Seth Hetherington, Arlene R Hughes, et al. · The Lancet · 807
International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology · 126
Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial
2017 · Francisco M Marty, Joan Vidal-Puigserver, et al. · The Lancet Respiratory Medicine · 106
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis
2015 · James G. Krueger, Mayte Suárez-Fariñas, et al. · PLoS ONE · 102
Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors
2002 · Michael Maguire, Denise Shortino, et al. · Antimicrobial Agents and Chemotherapy · 91
Once-Daily versus Twice-Daily Lamivudine, in Combination with Zidovudine and Efavirenz, for the Treatment of Antiretroviral-Naive Adults with HIV Infection: A Randomized Equivalence Trial
2004 · E. DeJesus, D. McCarty, et al. · Clinical Infectious Diseases · 59
Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR)
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology · 47
Intravenous Zanamivir in Hospitalized Patients With Influenza
2017 · John S. Bradley, Jeffrey L. Blumer, et al. · PEDIATRICS · 44
Avanti 3: A Randomized, Double-Blind Trial to Compare the Efficacy and Safety of Lamivudine plus Zidovudine versus Lamivudine plus Zidovudine plus Nelfinavir in HIV-1-Infected Antiretroviral-Naive Patients
2001 · Martin Gartland, N Clumeck, et al. · Antiviral Therapy · 43
PDF
Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
2021 · Michael J. Kennelly, Thomas Rhodes, et al. · Advances in Therapy · 37
PDF
Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study
2021 · Susann Varano, David Staskin, et al. · Drugs & Aging · 28
PDF
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
2018 · Lisa L. Ross, Denise Shortino, et al. · AIDS Research and Human Retroviruses · 23
PDF
Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study
2020 · Jeffrey Frankel, Susann Varano, et al. · International Journal of Clinical Practice · 22
PDF
Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis
2020 · Michael Kennelly, Ronald Wielage, et al. · Drugs in Context · 19
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
2021 · Jeffrey Frankel, David Staskin, et al. · Advances in Therapy · 13
PDF
Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
2022 · David Staskin, Jeffrey Frankel, et al. · International Journal of Clinical Practice · 12
PDF
Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza
2019 · Peiying Zuo, Jon Collins, et al. · Clinical and Translational Science · 5
PDF
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind , placebo‐controlled phase 2 trial
2022 · Brian E. Lacy, Jennifer King, et al. · Neurogastroenterology & Motility · 4
PDF
Pd21-01 Once-daily Vibegron 75 Mg for Overactive Bladder (oab): Double-blind 52-week Results From an Extension Study of the International Phase 3 Trial (empowur)
2020 · David Staskin*, Jeffrey Frankel, et al. · The Journal of Urology · 3
Pd21-02 Efficacy of Once-daily Vibegron 75 Mg for Overactive Bladder (oab) in Older Patients: the Empowur Randomized, International, Phase 3 Study
2020 · Jeffrey Frankel*, David Staskin, et al. · The Journal of Urology · 2
Safety, Tolerability and Pharmacokinetics (PK) of Intravenous Zanamivir (IVZ) Treatment in Hospitalized Pediatric and Adolescent Patients with Influenza: A Phase II Open-Label, Multicenter, Single- Arm Study
2016 · Jeffrey Blumer, John S. Bradley, et al. · Open Forum Infectious Diseases · 2
PDF
Mp63-15 Vibegron for the Treatment of Patients With Dry Overactive Bladder: a Subgroup Analysis From the Empowur Trial
2021 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology · 1
Reply by Authors
2021 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology
Reply by Authors
2020 · David Staskin, Jeffrey Frankel, et al. · The Journal of Urology
Works count: 27
Citation count: 4,294
H-index: 15
I10-index: 17
Year
Topic
Type